Lexaria Bioscience is a biotechnology company pursuing the enhancement of the bioavailability of a range of active pharmaceutical ingredients (API) using its proprietary DehydraTECH drug delivery technology. Co.'s patent portfolio includes patent family applications or grants pertaining to Co.'s method of improving bioavailability and taste, and the use of DehydraTECH as a delivery platform for a variety of APIs encompassing all cannabinoids including tetrahydrocannabinol; fat soluble vitamins; non-steroidal anti-inflammatory drugs pain medications; and nicotine and its analogs. Co. has identified two reportable segments: Intellectual Property Licensing and B2B Production. The LEXX stock yearly return is shown above.
The yearly return on the LEXX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LEXX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|